Skin
One focus of the lab is developing chemical architectures for local delivery of siRNAs to the skin. We have identified hydrophobic constructs that, upon intradermal injection and transdermal application, can lead to potent skin silencing in multiple species. This work has resulted in multiple applications, and our first siRNAs, developed with Alys Pharmaceuticals, have achieved IND approval and will enter the clinic for the treatment of alopecia areata.
News: